The aim of this study was to evaluate the efficacy of different doses of Ukrain in the treatment of 75 breast cancer patients. Patients were divided into three groups. Group I (25 patients) and group II (25 patients) were treated with 50 mg and 100 mg Ukrain, respectively, before surgery. The remaining 25 patients served as controls (no Ukrain treatment). Both clinical observations and laboratory parameters indicate that both doses of Ukrain tested had a similar beneficial effect on patient outcome and may be indicated for presurgical treatment of patients with breast cancer.